5:02 PM
Feb 06, 2009
 |  BC Extra  |  Top Story

FDA approves ATryn

FDA approved a BLA from GTC (NASDAQ:GTCB) for ATryn to prevent peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. FDA's Center for Veterinary...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >